Clinical Focus

  • Diabetes
  • Clinical Informatics
  • Pediatric Endocrinology

Academic Appointments

Administrative Appointments

  • Medical Director of Mobile Health, Stanford Children's Health (2014 - Present)
  • Clinical Staff, California Pacific Medical Center (2013 - Present)
  • Physician Lead, Endocrine/Diabetes Informatics, Lucile Packard Children's Hospital (2013 - Present)

Honors & Awards

  • Consulting Fellow Teaching Award, Lucile Packard Children's Hospital (2013)
  • Child Health Research Institute Trainee Support Award, Stanford Spectrum Child Health (2012-2013)
  • Research Training Grant Award, Genentech Center for Clinical Research in Endocrinology (2012-2013)
  • Stanford Society of Physician Scholars, Stanford University (2011-present)
  • Alan Krensky, MD, Endowed Clinical Fellow in Endocrinology, Stanford University (2010-2011)
  • Pediatric Resident Teaching Honor Roll, Loyola University Chicago (2009 and 2010)
  • St. Ignatius Peer Teaching Award, Stritch School of Medicine (2005)

Boards, Advisory Committees, Professional Organizations

  • Affiliated Faculty, Stanford Bio-X (2014 - Present)
  • Epic Systems Steering Board Member for Pediatric Endocrinology, Epic (2014 - Present)

Professional Education

  • Board Certification: Pediatric Endocrinology, American Board of Pediatrics (2013)
  • American Board of Pediatrics, Pediatric Endocrinology (2013)
  • Fellowship:Stanford University Medical Center-Endocrinology (2013) CA
  • Residency:Loyola University Chicago Stritch School Of Medicine (2010) IL
  • Board Certification: Pediatrics, American Board of Pediatrics (2009)
  • Residency:Loyola University Chicago Stritch School Of Medicine (2009) IL
  • Internship:Loyola University Chicago Stritch School Of Medicine (2007) IL
  • Medical Education:Loyola University Chicago Stritch School Of Medicine (2006) IL
  • B.S., University of Illinois, Cell & Structural Biology Major; Chemistry Minor (2002)

Research & Scholarship

Current Research and Scholarly Interests

Clinical translational research: improved detection techniques for diagnostic and predictive biomarkers of type 1 diabetes, and characterization of novel biomarker trends in the at-risk population. Our group is additionally investigating potential dietary and environmental triggers of type 1 diabetes.

Clinical informatics: optimization of the electronic medical record to support comprehensive and efficient multi-disciplinary approaches to outpatient and inpatient pediatric diabetes care and teaching. We are working toward a common platform for real-time review of patient and device data, and shared data/learning among institutions connected by a common EMR, to improve the quality and efficiency of pediatric diabetes care.


Journal Articles

  • The development of next-generation screening and diagnostic platforms will change diabetes care. Expert review of molecular diagnostics Kumar, R. B., Gupta, M., Feldman, B. J. 2015; 15 (3): 291-294


    Diabetes mellitus is a common disease with a rising incidence and the findings of hyperglycemia and glucosuria. However, there are multiple types of diabetes, each with distinct etiologies. The two major types of diabetes are type 1, which is caused by an autoimmune process, and type 2, which is thought to be primarily metabolic, resulting from insulin resistance, often in the setting of obesity. Historically, the distinction between these two types was obvious. Here, we discuss how this paradigm has dramatically changed because of both the evolving epidemiology of diabetes mellitus and new and emerging tools, and therapies to diagnose and treat diabetes. As we believe that understanding these changes is critical to providing optimal care to patients with diabetes, we have developed a novel plasmonic gold chip platform that is able to meet the new and emerging demands of modern diabetes care.

    View details for DOI 10.1586/14737159.2015.1002468

    View details for PubMedID 25583407

  • Primary ovarian insufficiency: a case series International Journal of Pediatric Endocrinology Pederson, J., Kumar, R. B., Hillard, P., Bachrach, L. K. 2015; in press
  • Letrozole vs Anastrozole for Height Augmentation in Short Pubertal Males: First Year Data JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM Neely, E. K., Kumar, R. B., Payne, S. L., Ranadive, S. A., Suchet, D. I. 2014; 99 (11): 4086-4093


    Aromatase inhibitors are used off-label to treat short stature in peripubertal boys.To investigate short- and long-term hormonal and auxologic differences in short pubertal boys treated with letrozole (L) or anastrozole (A).PATIENTS are seen for laboratory evaluation and physical examination every 6 months, bone age yearly, DEXA and spine film every 2 years. They will be followed until they reach their final height. This is a preliminary report after 1 year of treatment.A single academic children's hospital outpatient clinic.Boys with age >10 years, bone age ≤ 14 years, clinical and hormonal evidence of central puberty, and either height < fifth percentile or predicted adult height (PAH) more than 10 cm below mid-parental height (MPH).Letrozole (2.5 mg) or anastrozole (1 mg) was administered orally each day.Hormonal and clinical parameters, growth velocity, and change in bone age and PAH.Thirty-nine boys have completed 1 year of treatment. Baseline means were age 14.1 years, PAH 166 cm, and testosterone 198 ng/dL. At 1 year, letrozole resulted in higher LH (L 6.1 ± 2.5 vs A 3.2 ± 1.7 IU/L) and testosterone (1038 ± 348 vs 536 ± 216 ng/dL) with lower estradiol (2.8 ± 2.8 vs 5.6 ± 2.9 pg/mL) and IGF-1 (237 ± 51 vs 331 ± 79 ng/mL). First year growth velocities were identical (7.2 cm/year), but an increase in PAH was greater in the anastrozole group (4.2 ± 3.5 vs 1.4 ± 4.4 cm, p = 0.03) after 1 year.We present first-year data from a direct comparison of anastrozole and letrozole for height augmentation in short pubertal boys. Letrozole was more potent in hormonal manipulation than anastrozole. First-year growth velocities were comparable, but improvement in PAH was greater in the anastrozole group. It remains to be seen if positive PAH trends will translate to increase in final height in either group.

    View details for DOI 10.1210/jc.2014-2432

    View details for Web of Science ID 000346743100023

    View details for PubMedID 25137428

  • A plasmonic chip for biomarker discovery and diagnosis of type 1 diabetes. Nature medicine Zhang, B., Kumar, R. B., Dai, H., Feldman, B. J. 2014; 20 (8): 948-953


    Type 1 diabetes (T1D) is an autoimmune disease, whereas type 2 diabetes (T2D) results from insulin resistance and beta cell dysfunction. Previously, the onset of these two separate diseases was easily distinguished, with children being most at risk for T1D and T2D occurring in overweight adults. However, the dramatic rise in obesity, coupled with the notable increase in T1D, has created a large overlap in these previously discrete patient populations. Delayed diagnosis of T1D can result in severe illness or death, and rapid diagnosis of T1D is critical for the efficacy of emerging therapies. However, attempts to apply next-generation platforms have been unsuccessful for detecting diabetes biomarkers. Here we describe the development of a plasmonic gold chip for near-infrared fluorescence-enhanced (NIR-FE) detection of islet cell-targeting autoantibodies. We demonstrate that this platform has high sensitivity and specificity for the diagnosis of T1D and can be used to discover previously unknown biomarkers of T1D.

    View details for DOI 10.1038/nm.3619

    View details for PubMedID 25038825

  • Annular pancreas in identical twin newborns. Journal of Pediatric Surgery Hulvat, M. C., Kumar, R. B., Newman, B. M., Muraskas, J. K. 2005; 41 (8)

Stanford Medicine Resources: